Celcuity (NASDAQ:CELC) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Celcuity (NASDAQ:CELC) in a research report released on Friday morning,Benzinga reports. The firm currently has a $27.00 price target on the stock.

CELC has been the topic of several other reports. Needham & Company LLC restated a “buy” rating and set a $23.00 price objective on shares of Celcuity in a research note on Friday. Stifel Nicolaus raised their price objective on Celcuity from $39.00 to $42.00 and gave the company a “buy” rating in a research report on Monday, October 7th. Leerink Partners initiated coverage on Celcuity in a research note on Monday, July 22nd. They set an “outperform” rating and a $29.00 target price for the company. Leerink Partnrs upgraded Celcuity to a “strong-buy” rating in a research note on Monday, July 22nd. Finally, Lifesci Capital began coverage on shares of Celcuity in a research report on Monday, August 26th. They set an “outperform” rating and a $27.00 price objective for the company. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $29.17.

Celcuity Price Performance

Shares of CELC opened at $12.66 on Friday. The company has a current ratio of 14.95, a quick ratio of 14.95 and a debt-to-equity ratio of 0.54. The company’s fifty day simple moving average is $15.15 and its 200 day simple moving average is $16.04. Celcuity has a 1-year low of $11.51 and a 1-year high of $22.19. The company has a market cap of $468.80 million, a price-to-earnings ratio of -4.85 and a beta of 0.76.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its stake in shares of Celcuity by 27.6% in the third quarter. Geode Capital Management LLC now owns 630,369 shares of the company’s stock valued at $9,401,000 after acquiring an additional 136,518 shares in the last quarter. Barclays PLC raised its position in shares of Celcuity by 567.6% in the third quarter. Barclays PLC now owns 53,605 shares of the company’s stock valued at $800,000 after buying an additional 45,576 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in shares of Celcuity in the third quarter valued at approximately $205,000. XTX Topco Ltd acquired a new stake in Celcuity during the third quarter worth approximately $307,000. Finally, Wellington Management Group LLP bought a new position in Celcuity during the 3rd quarter worth $770,000. 63.33% of the stock is owned by institutional investors and hedge funds.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.